Request Demo
Last update 20 Mar 2025
Recombinant Fifteen Valent Human Papillomavirus Vaccine(E.coli)(Liaoning Chengda Biotechnology)
Last update 20 Mar 2025
Overview
Basic Info
Drug Type Prophylactic vaccine, Genetically engineered subunit vaccine |
Synonyms 15价HPV疫苗（成大生物） |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with Recombinant Fifteen Valent Human Papillomavirus Vaccine(E.coli)(Liaoning Chengda Biotechnology)CTR20241041
评价在 9-45 周岁健康女性受试者中接种重组十五价人乳头瘤病毒疫苗 （大肠埃希菌）的安全性、耐受性和免疫原性的随机、盲法、安慰剂和阳 性对照的Ⅰ期临床试验
[Translation] A randomized, blinded, placebo- and positive-controlled phase I clinical trial to evaluate the safety, tolerability, and immunogenicity of a recombinant 15-valent human papillomavirus vaccine (Escherichia coli) in healthy female subjects aged 9-45 years
100 Clinical Results associated with Recombinant Fifteen Valent Human Papillomavirus Vaccine(E.coli)(Liaoning Chengda Biotechnology)
Login to view more data
100 Translational Medicine associated with Recombinant Fifteen Valent Human Papillomavirus Vaccine(E.coli)(Liaoning Chengda Biotechnology)
Login to view more data
100 Patents (Medical) associated with Recombinant Fifteen Valent Human Papillomavirus Vaccine(E.coli)(Liaoning Chengda Biotechnology)
Login to view more data
100 Deals associated with Recombinant Fifteen Valent Human Papillomavirus Vaccine(E.coli)(Liaoning Chengda Biotechnology)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Anal intraepithelial neoplasia | Phase 2 | China | 18 Mar 2025 | |
| Anal intraepithelial neoplasia | Phase 2 | China | 18 Mar 2025 | |
| Uterine Cervical Dysplasia | Phase 2 | China | 18 Mar 2025 | |
| Uterine Cervical Dysplasia | Phase 2 | China | 18 Mar 2025 | |
| Vaginal intraepithelial neoplasia | Phase 2 | China | 18 Mar 2025 | |
| Vaginal intraepithelial neoplasia | Phase 2 | China | 18 Mar 2025 | |
| Vulvar intraepithelial neoplasia | Phase 2 | China | 18 Mar 2025 | |
| Vulvar intraepithelial neoplasia | Phase 2 | China | 18 Mar 2025 | |
| Vulvar Neoplasms | Phase 2 | China | 18 Mar 2025 | |
| Vulvar Neoplasms | Phase 2 | China | 18 Mar 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free